Riding On Exosome Potential, Evox Eyes Unicorn Status
UK Firm Completes £69.2m Series C Financing
Executive Summary
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.